TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features
暂无分享,去创建一个
Jaya M Satagopan | Qin Zhou | Victor E Reuter | Samson W Fine | W. Gerald | J. Satagopan | P. Scardino | V. Reuter | S. Tickoo | M. Leversha | S. Fine | H. Al-Ahmadie | A. Gopalan | Peter T Scardino | William L Gerald | Hikmat A Al-Ahmadie | Satish K Tickoo | Margaret A Leversha | Anuradha Gopalan | Qin C Zhou
[1] Daniel S. Miller,et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.
[2] O. Ludkovski,et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.
[3] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[4] W. Gerald,et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.
[5] R. Dhir. Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy , 2010 .
[6] J. Epstein. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy , 2004, Modern Pathology.
[7] Adam S. Kibel,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007 .
[8] P. Humphrey,et al. Diagnosis of adenocarcinoma in prostate needle biopsy tissue , 2007, Journal of Clinical Pathology.
[9] A. Partin,et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.
[10] D. Gleason,et al. Histologic Grading and Staging of Prostatic Carcinoma , 1981 .
[11] Sten Nilsson,et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens , 2005, Scandinavian journal of urology and nephrology. Supplementum.
[12] T. Tammela,et al. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.
[13] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.
[14] E. Platz,et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas , 2009, Modern Pathology.
[15] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[16] M. Cooperberg,et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. , 2005, The Journal of urology.
[17] U. Ferreira,et al. Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy. , 2008, International braz j urol : official journal of the Brazilian Society of Urology.
[18] W. Isaacs,et al. TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma , 2009, Modern Pathology.
[19] J. Epstein,et al. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance , 2006, Modern Pathology.
[20] J. Epstein,et al. Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. , 1999, The American journal of surgical pathology.
[21] S. Leung,et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.
[22] H. Scher. Management of prostate cancer after prostatectomy: treating the patient, not the PSA. , 1999, JAMA.
[23] Yao-Tseng Chen,et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.
[24] Ximing J. Yang,et al. Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy: An Interobserver Study among Experts in Genitourinary Pathology , 2008, The American journal of surgical pathology.
[25] M. Leversha. Mapping of genomic clones by fluorescence in situ hybridization. , 2001, Methods in molecular biology.
[26] D. Gleason,et al. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. , 1974, The Journal of urology.
[27] R. Shah,et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.
[28] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[29] J. McNeal,et al. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. , 1996, The American journal of surgical pathology.
[30] M. Rubin,et al. Morphological features of TMPRSS2–ERG gene fusion prostate cancer , 2007, The Journal of pathology.
[31] R. Shah,et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma , 2009, Modern Pathology.
[32] D. Chan,et al. Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .
[33] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[34] D. Bostwick,et al. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. , 2009, Archives of pathology & laboratory medicine.
[35] C. LaFargue,et al. TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a Canadian cohort , 2009, Cancer biology & therapy.
[36] M. Rubin,et al. TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.
[37] I. Panagopoulos,et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .
[38] Myron Tanncnbaum,et al. Urologic pathology: The prostate , 1977 .
[39] Arul M Chinnaiyan,et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.
[40] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[41] J. Brooks,et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis , 2007, Modern Pathology.
[42] J. Trachtenberg,et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.
[43] J. Epstein,et al. Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy: A Study of 47 Cases , 2008, The American journal of surgical pathology.
[44] Murali Varma,et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. , 2002, Archives of pathology & laboratory medicine.
[45] Michael W Kattan,et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M E Hammond,et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.